ACIU - AC Immune Announces Upcoming Presentations at AD/PD™ 2024 | Benzinga
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
- Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024)
- Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies
Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. In addition, Andrea Pfeifer, Ph.D., CEO of AC Immune SA will lead an industry symposium exploring the latest clinical advances in the diagnosis and treatment of alpha-synuclein pathologies.
Industry Symposium: State-of-the-art of treatment and diagnosis of alpha-synuclein pathologies
Session Date/Time: March 6, 2024 at 8:40 – 10:40 am WET
Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune SA
Recent developments in the diagnosis of synucleinopathies
Presenter: Werner Poewe, M.D. (Medical University of Innsbruck, Austria)
Time: 8:45 – 9:10 am WET
Development of an a-syn-PET tracer for alpha-synucleinopathies
Presenter: Francesca Capotosti, Ph.D. (AC Immune)
Time: 9:10 – 9:25 am WET
New therapeutic approaches in Parkinson's disease
Presenter: Fabrizio Stocchi, M.D., Ph.D. (University San Raffaele Roma, Italy)
Time: 9:25 – 9:45 am WET
Morphomer a-syn: small molecules targeting a-syn for the treatment of PD
Presenter: Elpida Tsika, Ph.D. (AC Immune)
Time: 9:45 – 10:05 am WET
Active immunotherapy ACI-7104.056 in early PD: update from the Phase 2 trial VacSYn
Presenter: Nuno Mendonça, M.D. (AC Immune)
Time: 10:05 – 10:20 am WET
Oral Presentations
Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome
Presenter: Marija Vukicevic, Ph.D. (AC Immune)
Session: Therapeutic targets in AD: Tau proteins
Date/Time: March 8, 2024 at 8:55 – 9:10 am WET
Targeting TDP-43 with a vectorized full-length antibody decreases neuropathology in ...